Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pilot study evaluating the impact of ibudilast on prevention of chemotherapy-induced neurotoxicity and evaluating pharmacokinetics in metastatic gastro-intestinal cancer patients receiving oxaliplatin

Next Previous
Search
Trial Profile

A pilot study evaluating the impact of ibudilast on prevention of chemotherapy-induced neurotoxicity and evaluating pharmacokinetics in metastatic gastro-intestinal cancer patients receiving oxaliplatin

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibudilast (Primary) ; Capecitabine; Fluorouracil; Oxaliplatin
  • Indications Chemotherapy-induced damage; Peripheral neuropathies
  • Focus Therapeutic Use

    • Most Recent Events

    • 24 Sep 2020 According to a MediciNova media release, positive clinical findings published in Cancer Chemotherapy and Pharmacology regarding MN-166 (ibudilast) as a treatment for prevention of chemotherapy-induced peripheral neuropathy (CIPN).
    • 24 Sep 2020 Results published in the MediciNova Media Release
    • 07 Aug 2019 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top